Imatinib mesylate improves insulin sensitivity and glucose disposal rates in rats fed a high-fat diet
Authors:
Open Access
- 30 November 2007
- journal article
- Published by Portland Press Ltd. in Clinical Science
- Vol. 114 (1) , 65-71
Abstract
The aim of the present study was to investigate whether imatinib affects insulin sensitivity and glucose disposal in HF (high-fat)-fed rats. Sprague–Dawley rats were fed either a standard pelleted rat food (low-fat diet) or an HF diet (60% fat) for 8 weeks. During the last 10 days of the HF diet regime, rats received saline alone or imatinib (50 or 100 mg/kg of body weight) daily by gavage. The higher dose of imatinib resulted in a decreased psoas fat pad weight in the HF-treated rats. Under euglycaemic hyperinsulinaemic clamp conditions, HF-fed rats exhibited increased insulin concentrations and decreased glucose disposal. The lower (50 mg/kg of body weight), but not the higher (100 mg/kg of body weight), dose of imatinib normalized insulin sensitivity and glucose disposal without affecting glucose metabolism in low-fat-fed rats. Hepatic glucose production at both fasting and hyperinsulinaemic conditions was only weakly affected by imatinib. We conclude that a moderate dose of imatinib efficiently counteracts HF-induced peripheral insulin resistance, and that further studies on the mechanisms by which imatinib increases insulin action in muscle and fat tissues might generate novel strategies for the treatment of Type 2 diabetes.Keywords
This publication has 22 references indexed in Scilit:
- Imatinib and Type 2 DiabetesEndocrine Practice, 2007
- Imatinib mesylate (Gleevec) protects against streptozotocin-induced diabetes and islet cell death in vitroCell Biology International, 2006
- Amelioration of diabetes by imatinib mesylate (Gleevec®): role of ‐cell NF‐KB activation and anti‐apoptotic preconditioningThe FASEB Journal, 2006
- Paraneoplastic Insulin Resistance Syndrome in Advanced Aggressive Fibromatosis (Desmoid Tumor) Treated by Imatinib MesylateDiabetes Care, 2006
- Non–Islet-Cell Tumor Induced Hypoglycemia in Patients With Advanced Gastrointestinal Stromal Tumor Possibly Worsened By ImatinibJournal of Clinical Oncology, 2006
- Imatinib and Regression of Type 2 DiabetesNew England Journal of Medicine, 2005
- Imatinib Mesylate May Improve Fasting Blood Glucose in Diabetic Ph+ Chronic Myelogenous Leukemia Patients Responsive to TreatmentJournal of Clinical Oncology, 2004
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- ARG tyrosine kinase activity is inhibited by STI571Blood, 2001